Programme Thesis
The ADDF-Harrington Scholar award funds early-stage, breakthrough discoveries with clear commercial potential to treat or prevent Alzheimer's disease, related dementias, or age-related cognitive decline. It exists to bridge the gap between academic research and clinical translation by providing both funding and drug-development expertise from Harrington's industry-savvy network.
Selection Criteria
- Innovation and creativity: the proposed approach must represent a paradigm shift or novel mechanism, not incremental work.
- Clinical impact potential: clear path to treating or preventing Alzheimer's/dementia/cognitive decline, with a plausible therapeutic hypothesis.
- Commercial viability: the project must have a tangible route to a drug, diagnostic, or therapeutic platform that can attract pharma investment or licensing.
- Feasibility and rigor: preliminary data, well-defined milestones, and a realistic experimental plan within the award period.
- Applicant's track record: demonstrated productivity in relevant fields, though early-career researchers are eligible if the science is compelling.
- Alignment with ADDF mission: focus on Alzheimer's, related dementias, or cognitive aging; projects in other CNS areas (e.g., addiction) require explicit mechanistic overlap.
Past Winners / Cohort Profiles
Past winners are typically academic researchers (PhD or MD/PhD) at universities or research institutes, often with a background in neuroscience, pharmacology, or drug discovery. Examples include Travis Dunckley (ASU-Banner Neurodegenerative Disease Research Center), who highlighted the value of Harrington's commercial expertise. Archetypes: a senior postdoc or junior faculty with a novel target or therapeutic candidate (small molecule, antibody, gene therapy) for Alzheimer's, and a clear plan for preclinical validation and IP protection.
Ideal Candidate Fingerprint
The ideal applicant is an academic scientist (often at a university or nonprofit research institute) with a breakthrough discovery in Alzheimer's or dementia biology—such as a new disease mechanism, drug target, or biomarker—that has strong preliminary data and a credible path to a commercial therapeutic. They should be open to mentorship from Harrington's drug-development experts and able to articulate a clear translational plan.
Recommended Framing
Eniola should frame the CCT model not as an addiction framework but as a general mechanism of aberrant synaptic consolidation that is directly relevant to Alzheimer's pathology—specifically, the role of dopamine-dependent RPE signals, NMDAR plasticity, and affective contrast in driving maladaptive memory encoding in early AD. She can argue that the same tripartite ODE system, calibrated with Bayesian methods, can be repurposed to model and predict interventions for cognitive decline, positioning her as a computational pharmacologist offering a novel in silico screening platform for dementia therapeutics. Her independent, multi-domain profile (pharmacist + modeler + software engineer) and endorsements from Berridge, Gershman, Daw, and Mattar lend credibility, but she must explicitly connect her work to Alzheimer's biology and commercial translation.
Watch Out
Primary red flag: the CCT model is explicitly an addiction-neuroscience framework, not dementia-specific; the programme requires a direct Alzheimer's/dementia angle. Eniola is an independent researcher without a formal academic affiliation (though enrolled in an M.Sc. program), which may raise concerns about institutional support and infrastructure for drug development. She has no prior work in Alzheimer's or neurodegeneration, and her computational models lack wet-lab validation or a clear experimental plan for preclinical testing. The award likely expects a PI at a university or research institute; independent status may be a disadvantage. Also, the deadline is June 8, 2026, which is very soon—she would need to rapidly reframe and submit a compelling proposal.
Research History
2026-07-26 18:43 · medium confidence